Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Hani M. Babiker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9368-6296; OpenAlex author ID A5059022515, A5130718689. Sources: ClinicalTrials.gov.

Their work

Papers
36 (first author 2, last author 15)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
77
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers, 1 trial · 2023: 4 papers · 2024: 5 papers · 2025: 5 papers · 2026: 10 papers

Papers 36

  1. Tumor Treating Fields (TTFields) potentiate cisplatin efficacy and remodel the transcriptional landscape in preclinical models of pancreatic ductal adenocarcin… Last author DOI 10.1016/j.canlet.2026.218651↗
  2. AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117777↗
  3. KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. Co-author DOI 10.1186/s13045-026-01863-x↗
  4. Association Between Computed Tomography-Based AI-Derived Body Composition and Survival in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ajg.0000000000003896↗
  5. Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies. First author DOI 10.21037/apc-26-0014↗
  6. Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. Last author DOI 10.21037/apc-26-0044↗
  7. Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? -a decade of debate! Co-author DOI 10.21037/jgo-2025-1-988↗
  8. Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. Co-author DOI 10.2147/dddt.s559325↗
  9. Intraperitoneal Chemotherapy Strategies in Pancreatic Ductal Adenocarcinoma: A Systematic Review of Hyperthermic Intraperitoneal Chemotherapy, Normothermic Int… Co-author DOI 10.3390/cancers18020182↗
  10. Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy. Last author DOI 10.3390/cells15090845↗
  11. Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. Last author DOI 10.1080/13543784.2025.2473698↗
  12. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  13. Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. Last author DOI 10.21037/jgo-2025-100↗
  14. Case Report: Gemcitabine-induced membranoproliferative glomerulonephritis with immune complexes in a patient with metastatic pancreatic cancer. Co-author DOI 10.3389/fmed.2025.1666859↗
  15. Tumor-Treating Fields Alter Nanomechanical Properties of Pancreatic Ductal Adenocarcinoma Cells Co-Cultured with Extracellular Matrix. Co-author DOI 10.3390/jfb16050160↗
  16. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. Last author DOI 10.1007/s11523-024-01088-3↗
  17. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.mtbio.2024.101199↗
  18. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer. Last author DOI 10.1080/14656566.2024.2304125↗
  19. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Last author DOI 10.2147/ceg.s390655↗
  20. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  21. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Last author DOI 10.1080/13543784.2023.2206558↗
  22. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  23. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Last author DOI 10.5306/wjco.v14.i8.285↗
  24. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing. Last author DOI 10.7759/cureus.37239↗
  25. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-p… Co-author DOI 10.1007/s10637-021-01164-9↗
  26. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Last author DOI 10.1080/14656566.2022.2149322↗
  27. Contemporary Management of Pancreatic Cancer from an Internist Perspective. Co-author DOI 10.1016/j.amjmed.2020.11.009↗
  28. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot C… Co-author DOI 10.1001/jamaoncol.2019.3394↗
  29. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Co-author DOI 10.1080/14740338.2020.1715939↗
  30. Quantitative metric for assessment of pancreatic ductal adenocarcinoma treatment response in T1-weighted gadolinium-enhanced magnetic resonance imaging. Co-author DOI 10.21037/apc-20-25↗
  31. Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institu… Last author DOI 10.21037/apc.2020.02.01↗
  32. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1080/13543784.2019.1557145↗
  33. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1080/13543784.2019.1632289↗
  34. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal a… Last author DOI 10.21037/apc.2019.06.01↗
  35. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology … Last author DOI 10.1007/s40801-018-0137-x↗
  36. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Co-author DOI 10.1097/cad.0000000000000437↗

Trials 1

  1. Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC Principal investigator NCT04605913↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitesh J. Borad · 11 shared papers, 2017–2026 · strength 2.37
  2. Debabrata Mukhopadhyay · 6 shared papers, 2024–2026 · strength 1.88
  3. Ahmed Adel Fouad Abdelhakeem · 5 shared papers, 2025–2026 · strength 1.85
  4. Umair Majeed · 7 shared papers, 2023–2026 · strength 1.73
  5. Tanios Bekaii‐Saab · 6 shared papers, 2021–2026 · strength 1.25
  6. Santanu Bhattacharya · 4 shared papers, 2024–2026 · strength 1.15
  7. Douaa Albelal · 4 shared papers, 2024–2026 · strength 1.08
  8. Himil J Mahadevia · 4 shared papers, 2023–2025 · strength 0.95
  9. Nayef Hikmat Abdel-Razeq · 2 shared papers, 2025–2026 · strength 0.87
  10. Mohamad Bassam Sonbol · 4 shared papers, 2021–2026 · strength 0.84
  11. Hari Krishnareddy Rachamala · 3 shared papers, 2024–2026 · strength 0.79
  12. Ahmed Elhariri · 3 shared papers, 2023–2025 · strength 0.63
  13. Osama M. Mosalem · 2 shared papers, 2024–2025 · strength 0.62
  14. Daruka Mahadevan · 4 shared papers, 2019–2022 · strength 0.57
  15. Tanmay Kulkarni · 2 shared papers, 2025–2026 · strength 0.56
  16. Nency Ganatra · 2 shared papers, 2026 · strength 0.55
  17. Jason Scott Starr · 3 shared papers, 2023 · strength 0.54
  18. Jing Wang · 2 shared papers, 2023–2024 · strength 0.50
  19. Nguyen H. Tran · 2 shared papers, 2024–2025 · strength 0.49
  20. Alejandro Recio‐Boiles · 4 shared papers, 2019–2022 · strength 0.47
  21. Krishnendu Pal · 2 shared papers, 2024–2026 · strength 0.43
  22. Naga Malleswara Rao Nakka · 2 shared papers, 2024–2026 · strength 0.43
  23. Ali McBride · 4 shared papers, 2019–2020 · strength 0.43
  24. Sreenivasa Rao Chandana · 3 shared papers, 2019–2022 · strength 0.43
  25. Tucker W. Coston · 2 shared papers, 2023 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.